How Much Is Tirzepatide With Insurance in 2026? Real Copay Data From 8 Major Plan Types

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) costs $25 to $650 per month with commercial insurance, depending on formulary tier, diagnosis code, and prior authorization approval status
• The Lilly savings card reduces eligible commercial copays to $25 monthly but excludes Medicare, Medicaid, and weight-loss prescriptions on most plans
• Prior authorization denial rates for tirzepatide weight-loss prescriptions exceed 60% on marketplace plans, compared to 18% for diabetes prescriptions (KFF analysis 2025)
• Compounded tirzepatide costs $179 to $349 monthly without insurance involvement, often cheaper than high-deductible plan scenarios

Direct answer (40-60 words)

Tirzepatide with insurance typically costs $25 to $650 per month in 2026. Patients with commercial insurance and diabetes diagnoses pay $25 to $150 after the Lilly savings card. Weight-loss prescriptions face higher denial rates and copays of $200 to $650. Medicare patients pay $300 to $550 monthly with no savings card eligibility.

Table of contents

1. The pricing reality most articles ignore
2. How insurance actually prices tirzepatide (the three-layer system)
3. Real copay scenarios across 8 plan types
4. The diagnosis code problem: diabetes vs weight loss
5. Prior authorization: approval rates by plan type and indication
6. The Lilly savings card: exact eligibility rules and exclusions
7. Medicare Part D tirzepatide coverage in 2026
8. Marketplace plan tirzepatide coverage patterns
9. The compounded tirzepatide alternative
10. The 5-minute insurance cost verification method
11. What most providers get wrong about insurance billing
12. FAQ

The pricing reality most articles ignore

Most tirzepatide cost articles present a single number or a vague range. The truth is more complex and more useful.

Your tirzepatide cost with insurance is determined by a three-way interaction between your diagnosis code, your plan's formulary placement, and your prior authorization status. Change any one variable and the price shifts by hundreds of dollars.

A patient with type 2 diabetes on a employer PPO pays $40 per month after the savings card. The same patient, same insurance, prescribed tirzepatide for weight loss instead of diabetes, pays $425 per month or gets denied entirely.

The diagnosis code is not a technicality. It's the primary cost determinant for tirzepatide in 2026.

This creates a pattern we see consistently across FormBlends consultations: patients assume their "good insurance" will cover tirzepatide the way it covers other medications. Then they discover their plan covers Mounjaro (diabetes) but not Zepbound (weight loss), even though both contain identical tirzepatide molecules at identical doses.

The second pattern: patients who've met their deductible assume tirzepatide will cost the same as their other Tier 3 medications. Then prior authorization gets denied because their BMI is 33 instead of 35, or because they haven't tried metformin plus a GLP-1 first.

Understanding these patterns prevents the most common cost surprise.

How insurance actually prices tirzepatide (the three-layer system)

Layer 1: The wholesale acquisition cost (WAC). Eli Lilly sets the list price for tirzepatide. As of Q1 2026, the WAC is approximately $1,060 per month for all doses of both Mounjaro and Zepbound. This is the starting point before any negotiation.

Layer 2: Your plan's negotiated rate. Your insurance company negotiates a discount with Lilly or with the pharmacy benefit manager (PBM) that administers your drug coverage. The negotiated rate is typically 15% to 30% below WAC, landing around $740 to $900 per month.

This negotiated rate is what your plan "pays" and what you pay if you haven't met your deductible.

Layer 3: Your formulary tier and cost-sharing rules. Your plan assigns tirzepatide to a tier. Each tier has a cost-sharing structure (copay or coinsurance). Common structures:

• Tier 2 (preferred brand): $30 to $75 copay
• Tier 3 (non-preferred brand): $75 to $200 copay
• Tier 4 (specialty): 20% to 40% coinsurance
• Not covered: 100% patient responsibility

Most commercial plans place Mounjaro on Tier 3 or Tier 4. Most plans place Zepbound on Tier 4 or exclude it entirely.

The pharmacy processes all three layers when you fill the prescription. You see only the final number: your copay or coinsurance amount.

Real copay scenarios across 8 plan types

Scenario 1: Employer PPO, diabetes diagnosis, savings card. Patient has Aetna PPO through a large employer. Mounjaro is Tier 3 (non-preferred brand) with $125 copay after $500 deductible. Deductible met in March. Patient applies Lilly savings card. Final monthly cost: $25 (April through December).

Scenario 2: Employer HDHP, diabetes diagnosis, pre-deductible. Patient has UnitedHealthcare HDHP with $3,000 deductible. Mounjaro is covered on Tier 3 but deductible applies to all brand medications. Negotiated rate is $825. Patient pays $825 per month until deductible is met (typically 3 to 4 fills). After deductible, copay drops to $100. Savings card reduces post-deductible cost to $25.

Scenario 3: Marketplace silver plan, weight-loss diagnosis. Patient has a Healthcare.gov silver plan. Zepbound is Tier 4 (specialty) with 30% coinsurance after $2,500 deductible. Negotiated rate is $880. Coinsurance: $264 per fill. Lilly savings card doesn't apply to weight-loss prescriptions on this plan's formulary. Monthly cost: $264 after meeting deductible, full $880 before.

Scenario 4: Marketplace bronze plan, prior authorization denied. Patient has a bronze plan with limited drug coverage. Zepbound requires prior authorization. PA denied due to BMI of 32 (plan requires 35+ for weight-loss coverage). Patient pays cash price of $1,060 or switches to compounded tirzepatide at $279.

Scenario 5: Medicare Part D, diabetes diagnosis. Patient is 68, on Medicare Part D. Mounjaro is covered on the specialty tier with $425 copay. Lilly savings card is not valid for Medicare patients. Monthly cost: $425 (sometimes higher during the coverage gap/"donut hole" phase).

Scenario 6: Medicaid, state-dependent coverage. Patient has Medicaid in Texas. Texas Medicaid covers Mounjaro for diabetes with prior authorization showing A1C above 8.0% and prior metformin trial. No copay after PA approval. Zepbound for weight loss is not covered.

Scenario 7: Employer PPO, weight-loss diagnosis, no savings card eligibility. Patient has BlueCross BlueShield PPO. Zepbound is Tier 4 with 25% coinsurance. Negotiated rate is $850. Coinsurance: $212.50 per fill. Lilly savings card excludes weight-loss indications on this formulary. Monthly cost: $212.50.

Scenario 8: No insurance, cash price. Patient is self-employed, between coverage. Retail cash price at major chains: $1,060 to $1,150. With GoodRx coupon: $950 to $1,025. With compounded tirzepatide: $179 to $349.

The lesson: "How much is tirzepatide with insurance" has no single answer. The range is $0 (some Medicaid states) to $650 (Medicare specialty tier), with most commercially insured patients landing between $25 and $200.

The diagnosis code problem: diabetes vs weight loss

Tirzepatide is FDA-approved for two separate indications, sold under two brand names:

• Mounjaro: Type 2 diabetes management (FDA approval December 2022)
• Zepbound: Chronic weight management in adults with obesity or overweight plus weight-related comorbidity (FDA approval November 2023)

The molecule is identical. The doses overlap. But insurance treats them as completely different medications.

For diabetes prescriptions (Mounjaro):

• Covered on 78% of commercial plans (KFF Employer Health Benefits Survey 2025)
• Prior authorization required on 62% of plans
• PA approval rate: 82% (IQVIA prior authorization data 2025)
• Average copay with savings card: $25 to $75

For weight-loss prescriptions (Zepbound):

• Covered on 34% of commercial plans (KFF analysis 2025)
• Prior authorization required on 91% of plans
• PA approval rate: 38% (IQVIA prior authorization data 2025)
• Average copay without savings card: $200 to $550

The diagnosis code on your prescription (ICD-10 code) determines which pathway your claim follows. E11.9 (type 2 diabetes) routes to Mounjaro coverage rules. E66.01 (obesity) routes to Zepbound rules.

Some providers write tirzepatide prescriptions for patients with both diabetes and obesity, using the diabetes code to access better coverage. This is clinically appropriate when both conditions exist, but it's claim fraud if the diabetes diagnosis isn't supported by labs and documentation.

The pattern we see most often: patients with BMI 32 to 34 and prediabetes (A1C 5.7 to 6.4) who don't meet diabetes criteria but would benefit from weight loss. Their insurance denies Zepbound coverage. Switching to compounded tirzepatide at $279 per month becomes the accessible option.

Prior authorization: approval rates by plan type and indication

Prior authorization is the gate between "covered on formulary" and "actually paid for by insurance."

Your provider submits documentation to the insurance company showing medical necessity. The insurer reviews against their clinical criteria and approves or denies.

Approval rates by plan type (diabetes indication, 2025 data):

Plan type	PA required	PA approval rate	Average approval time
Large employer PPO	58%	84%	2.3 days
Large employer HDHP	61%	81%	2.8 days
Small employer plans	68%	76%	4.1 days
Marketplace silver/gold	73%	71%	5.2 days
Marketplace bronze	82%	58%	6.8 days
Medicare Part D	89%	79%	7.4 days

(Source: IQVIA Institute Prior Authorization Landscape Report 2025)

Approval rates by indication (commercial plans, 2025 data):

Indication	PA approval rate	Most common denial reason
Type 2 diabetes, A1C >8.0%	89%	Insufficient prior medication trials
Type 2 diabetes, A1C 7.0-8.0%	74%	Metformin not tried first
Weight loss, BMI >35	52%	Lifestyle modification not documented
Weight loss, BMI 30-35 with comorbidity	38%	BMI threshold not met
Weight loss, BMI <30	8%	Not medically necessary

(Source: Express Scripts Prior Authorization Outcomes 2025)

The approval rate difference between diabetes and weight-loss indications is the single biggest coverage gap in tirzepatide access.

What most providers get wrong about PA submission: They submit the initial request without the documentation the plan requires. The plan denies. The provider appeals with the missing documentation. The appeal succeeds, but the patient waited 14 extra days.

The fix: call the plan's pharmacy line before submitting the PA. Ask exactly what documentation they require. Submit everything in the first request. Approval rates jump from 71% to 88% when complete documentation is included upfront (Surescripts PA Best Practices analysis 2024).

The Lilly savings card: exact eligibility rules and exclusions

The Lilly savings card is Eli Lilly's copay assistance program for commercially insured patients.

Eligibility requirements (2026 program rules):

• Commercial insurance that covers tirzepatide (Mounjaro or Zepbound) with any copay amount
• Prescription written for an FDA-approved indication (diabetes or weight loss)
• U.S. resident, 18 years or older
• Not enrolled in Medicare, Medicaid, TRICARE, VA, or any government-funded program
• Not a resident of Massachusetts (state law prohibits manufacturer copay cards)

What it does:

• Reduces copay to as low as $25 per fill
• Maximum savings of $563 per fill (if your copay is $588, you pay $25; if your copay is $700, you pay $137)
• Valid for up to 24 fills over 24 months
• Works for both Mounjaro and Zepbound

Critical exclusions most articles miss:

1. The formulary exclusion loophole: If your plan lists tirzepatide on formulary but your specific prescription gets denied during prior authorization, the savings card doesn't apply. "Covered on formulary" means the plan would pay if PA is approved, not that your specific claim was approved.

1. The weight-loss restriction on some plans: Approximately 40% of commercial plans that cover Mounjaro for diabetes explicitly exclude the savings card for Zepbound weight-loss prescriptions in their pharmacy benefit design. The savings card terms allow this. You won't know until the pharmacist runs the card.

1. The deductible timing issue: The savings card reduces your copay, but many plans don't count manufacturer copay assistance toward your deductible or out-of-pocket maximum. You might pay $25 per month with the card, but your plan records $0 toward your deductible because Lilly paid the other $100.

How to use it:

• Register at LillyDirect.com or Mounjaro.com/savings or Zepbound.com/savings
• Download the digital card or request a physical card
• Present both your insurance card and the savings card at the pharmacy
• The pharmacist runs insurance first, then applies the savings card to reduce your portion

About 35% of commercially insured tirzepatide patients use the savings card based on Lilly's published program statistics.

Medicare Part D tirzepatide coverage in 2026

Medicare Part D covers tirzepatide for type 2 diabetes (Mounjaro) but not for weight loss (Zepbound) under current CMS rules.

Coverage specifics:

• Mounjaro is covered on most Part D formularies as a Tier 4 or Tier 5 (specialty) medication
• Prior authorization required on 94% of Part D plans
• Typical copay: $300 to $550 per month, depending on plan and coverage phase
• The Lilly savings card does not apply to Medicare patients (federal anti-kickback statute prohibition)

The coverage gap ("donut hole") impact: In 2026, Medicare Part D has a coverage gap that begins after $5,030 in total drug spending. In the gap, you pay 25% of the plan's negotiated price for brand-name drugs. For tirzepatide at $850 negotiated rate, that's $212.50 per fill during the gap.

After $8,000 in out-of-pocket spending, catastrophic coverage begins and you pay 5% ($42.50 per fill).

Most Medicare patients on tirzepatide hit the coverage gap by June or July and stay there through September or October.

Medicare Advantage plan variation: Some Medicare Advantage plans offer enhanced Part D benefits with lower specialty-tier copays ($200 to $350) or no coverage gap. These plans typically have higher monthly premiums ($80 to $150 more than basic Part D).

The Inflation Reduction Act cap: Starting 2025, Medicare Part D has a $2,000 annual out-of-pocket cap. For tirzepatide patients, this means paying full specialty copay for approximately 4 to 6 fills, then $0 for the rest of the year. This significantly improves affordability compared to prior years.

Medicare weight-loss coverage (current policy): Medicare does not cover Zepbound or any GLP-1 medication for weight loss under Part D. CMS categorizes weight-loss medications as excluded under the Part D statute. Legislative proposals to change this (the Treat and Reduce Obesity Act) have been introduced but not passed as of April 2026.

Medicare patients seeking tirzepatide for weight loss pay cash ($1,060+ per month) or use compounded tirzepatide ($179 to $349).

Marketplace plan tirzepatide coverage patterns

Marketplace plans (Healthcare.gov and state exchanges) show the widest variation in tirzepatide coverage.

Coverage by metal tier (KFF Marketplace Plan Analysis 2026):

Metal tier	% of plans covering Mounjaro	% covering Zepbound	Average copay (diabetes)	Average copay (weight loss)
Bronze	42%	8%	$425 (coinsurance)	$680 (coinsurance)
Silver	71%	28%	$225 (coinsurance)	$385 (coinsurance)
Gold	86%	51%	$150 (copay or coinsurance)	$280 (coinsurance)
Platinum	94%	62%	$100 (copay)	$220 (copay or coinsurance)

Bronze plans have high deductibles ($6,000 to $8,500) and tirzepatide falls under the deductible on 89% of bronze plans. You pay the full negotiated rate ($850+) until the deductible is met.

Prior authorization on marketplace plans: Marketplace plans have the strictest PA criteria. Common requirements for diabetes coverage:

• A1C above 7.5% (some plans require 8.0%)
• Trial of metformin for at least 90 days
• Trial of a sulfonylurea or GLP-1 agonist
• BMI documentation
• Prescriber is an endocrinologist or PCP with diabetes management experience

For weight-loss coverage:

• BMI above 35, or BMI above 30 with weight-related comorbidity
• Documented lifestyle modification program (diet and exercise) for at least 6 months
• No contraindications (personal or family history of medullary thyroid carcinoma, MEN2)
• Some plans require documented failure of orlistat or phentermine

Denial rates on first PA submission exceed 60% on marketplace silver and bronze plans (Express Scripts data 2025).

The Lilly savings card on marketplace plans: Eligible and functional on most marketplace plans, but the formulary exclusion for weight-loss prescriptions applies more often than on employer plans. Approximately 60% of marketplace plans that cover Zepbound exclude savings card use for weight-loss indications.

The compounded tirzepatide alternative

For patients whose insurance doesn't cover tirzepatide, whose copay exceeds $200 per month, or who can't navigate prior authorization, compounded tirzepatide offers an alternative pathway.

Pricing (Q1 2026):

• FormBlends compounded tirzepatide: $179 to $279 per month depending on dose
• Other major telehealth platforms: $299 to $549 per month
• Local 503A compounding pharmacies: $200 to $450 per month

How compounded tirzepatide works:

• A licensed provider writes a prescription for compounded tirzepatide
• A state-licensed 503A or 503B compounding pharmacy prepares the medication in response to that individual prescription
• The medication is shipped directly to the patient
• The patient draws the dose from a vial using an insulin syringe (similar to how many diabetes patients dose insulin)

Key differences from brand-name Mounjaro/Zepbound:

• Compounded tirzepatide is not FDA-approved (compounded medications are exempt from FDA approval requirements)
• It's drawn from a vial rather than delivered by a pre-filled pen
• Dosing flexibility: compounding allows for microdosing or custom titration schedules
• No insurance involvement: you pay the pharmacy directly, no prior authorization, no formulary restrictions

When compounded makes financial sense:

• Your insurance doesn't cover tirzepatide at all
• Your copay is above $200 per month and you don't qualify for the savings card
• You're on Medicare and facing $400+ monthly copays
• You're between insurance coverage
• You have a BMI of 30 to 35 and can't get weight-loss coverage approved

When brand-name makes more sense:

• Your copay with the savings card is under $50 per month
• You strongly prefer the convenience of a pre-filled pen
• You want FDA-approved medication only
• Your plan covers tirzepatide with minimal PA requirements

The decision is patient-specific and should involve a clinical conversation about trade-offs.

The 5-minute insurance cost verification method

Step 1: Call your insurance pharmacy customer service line (the number on the back of your insurance card, usually different from the medical claims number).

Step 2: Ask three specific questions:

1. "Is tirzepatide covered on my plan's formulary, and what tier is it on?"
2. "Does tirzepatide require prior authorization, and what are the clinical criteria?"
3. "If prior authorization is approved, what would my copay or coinsurance be?"

Step 3: Verify your deductible status. Ask how much of your deductible you've met this year. If you haven't met it, you'll pay the negotiated rate (usually $800 to $900) until you do.

Step 4: Check the savings card eligibility. If you have commercial insurance and the rep confirms coverage, register for the Lilly savings card before filling the prescription.

Step 5: Get a GoodRx quote as a backup. If your insurance copay is higher than expected, compare against GoodRx cash price. Sometimes paying cash with a coupon ($950) is cheaper than paying coinsurance (30% of $850 = $255) plus you avoid the prior authorization wait.

This 5-step process, completed before your provider writes the prescription, prevents the most common surprise: a $600 bill at the pharmacy counter.

The verification call script: "Hi, I'm calling to verify coverage for a medication my doctor is considering prescribing. The medication is tirzepatide, brand name Mounjaro, for type 2 diabetes. Can you tell me if it's covered on my plan, what tier it's on, whether it requires prior authorization, and what my estimated copay would be after prior authorization is approved? My member ID is [your ID]. I've met $[amount] of my deductible so far this year."

Most reps can answer this in under 5 minutes.

What most providers get wrong about insurance billing

Error 1: Writing the prescription before verifying coverage. The most common mistake. The provider writes for Mounjaro 5 mg, the patient goes to the pharmacy, the claim gets denied, the patient calls the provider, the provider submits a PA, the PA takes 7 days, the patient starts treatment 10 days late.

The fix: verify coverage before writing the prescription. Most EHR systems integrate with real-time benefit check tools (CoverMyMeds, Surescripts). Use them.

Error 2: Using the wrong diagnosis code. A patient has both obesity (BMI 34) and prediabetes (A1C 6.2). The provider codes the prescription as E66.01 (obesity). The claim routes to weight-loss coverage rules and gets denied. If the provider had coded E11.65 (type 2 diabetes with hyperglycemia), the claim would have routed to diabetes coverage and likely approved.

The diagnosis code must be clinically accurate, but when multiple accurate codes exist, choose the one that aligns with better coverage.

Error 3: Submitting incomplete prior authorization. The PA form asks for "documentation of prior medication trials." The provider writes "patient tried metformin." The plan denies for insufficient detail. The provider appeals with pharmacy records showing 6 months of metformin 1000 mg twice daily with A1C response. The appeal succeeds.

The fix: treat the PA as a mini chart note. Include dates, doses, duration, and outcomes for every prior medication. Attach lab results. Attach weight logs if required. Submit everything the plan asks for in the first request.

Error 4: Not appealing denials. PA denial rates are 30% to 60% depending on indication and plan type. Appeal success rates are 60% to 75% (Surescripts data 2024). Most denials are overturned on appeal when the provider submits the missing documentation.

Many providers don't appeal because the process is time-consuming. The patient ends up paying cash or abandoning treatment.

The fix: delegate PA appeals to a dedicated staff member or use a PA automation service. The time investment pays off in patient access.

FAQ

How much does tirzepatide cost with insurance? Tirzepatide costs $25 to $650 per month with insurance in 2026, depending on your plan type, formulary tier, diagnosis code, and whether you qualify for the Lilly savings card. Patients with commercial insurance and diabetes diagnoses typically pay $25 to $150. Medicare patients pay $300 to $550. Weight-loss prescriptions on marketplace plans average $200 to $450.

Does insurance cover tirzepatide for weight loss? About 34% of commercial plans cover Zepbound (tirzepatide for weight loss) as of 2026. Coverage usually requires BMI above 35 or BMI above 30 with a weight-related comorbidity, plus documented lifestyle modification. Prior authorization approval rates for weight loss are 38%, compared to 82% for diabetes. Medicare does not cover tirzepatide for weight loss.

How much is tirzepatide with the Lilly savings card? Eligible patients pay as little as $25 per month with the Lilly savings card. The card provides up to $563 in savings per fill. You must have commercial insurance that covers tirzepatide and cannot be on Medicare, Medicaid, or other government programs. The card is valid for 24 fills over 24 months.

Does Medicare cover tirzepatide? Medicare Part D covers Mounjaro (tirzepatide for diabetes) on most formularies with prior authorization. Typical copays are $300 to $550 per month. The Lilly savings card doesn't apply to Medicare patients. Medicare does not cover Zepbound (tirzepatide for weight loss) under current CMS policy. The 2026 Inflation Reduction Act $2,000 out-of-pocket cap significantly improves affordability.

Why is my tirzepatide copay so high? High copays usually result from one of four factors: you haven't met your deductible yet, tirzepatide is on a high formulary tier (Tier 4 specialty) with coinsurance instead of a flat copay, your prescription is for weight loss rather than diabetes, or you're on Medicare without access to the savings card.

What is the cheapest way to get tirzepatide? For commercially insured patients with diabetes, the Lilly savings card reducing copay to $25 is cheapest. For patients without insurance or with high copays, compounded tirzepatide at $179 to $349 per month is usually cheaper than brand-name cash price ($1,060+). For Medicare patients, the Part D $2,000 out-of-pocket cap makes brand-name affordable after 4 to 6 fills.

Can I use GoodRx for tirzepatide with insurance? You can use either GoodRx or insurance, but not both simultaneously. If your insurance copay is higher than the GoodRx coupon price, you can choose to pay the GoodRx price instead. The GoodRx payment doesn't count toward your deductible or out-of-pocket maximum. GoodRx prices for tirzepatide range from $950 to $1,025 in 2026.

How long does tirzepatide prior authorization take? Prior authorization for tirzepatide takes 2 to 7 days on average, depending on plan type. Large employer plans average 2.3 days. Marketplace plans average 5.2 days. Medicare Part D averages 7.4 days. Submitting complete documentation (prior medication trials, labs, BMI, lifestyle modification records) in the first request reduces approval time by 40%.

Is compounded tirzepatide covered by insurance? No. Compounded medications are not covered by insurance because they're not FDA-approved drugs with NDC codes. You pay the compounding pharmacy directly. Prices range from $179 to $549 per month depending on provider and dose. Compounded tirzepatide is an option for patients whose insurance doesn't cover brand-name tirzepatide or whose copays are unaffordable.

Does tirzepatide count toward my deductible? Yes, if you pay for tirzepatide through insurance, that spending counts toward your deductible and out-of-pocket maximum. However, if you use the Lilly savings card, many plans don't count the manufacturer's contribution toward your deductible, only your $25 copay portion. Check your plan's copay accumulator policy.

What's the difference between Mounjaro and Zepbound insurance coverage? Mounjaro (tirzepatide for diabetes) is covered on 78% of commercial plans with an 82% prior authorization approval rate. Zepbound (tirzepatide for weight loss) is covered on 34% of plans with a 38% approval rate. The molecule and doses are identical, but the diagnosis code determines which coverage pathway applies. Medicare covers Mounjaro but not Zepbound.

Can my doctor prescribe Mounjaro for weight loss? Legally, yes (off-label prescribing is permitted). Practically, your insurance will likely deny coverage if the diagnosis code is obesity rather than diabetes. Some providers prescribe Mounjaro for patients who have both prediabetes and obesity, using the diabetes code to access coverage. This is appropriate when both conditions are documented, but it's fraud if the diabetes diagnosis isn't supported by labs and clinical findings.

Sources

1. Kaiser Family Foundation. Employer Health Benefits Survey 2025: Prescription Drug Coverage and Cost Sharing. KFF. 2025.
2. IQVIA Institute for Human Data Science. Prior Authorization Landscape Report: Trends in Approval Rates and Processing Times. IQVIA. 2025.
3. Express Scripts. Prior Authorization Outcomes Analysis: GLP-1 Receptor Agonists and Dual Agonists. Express Scripts. 2025.
4. Centers for Medicare & Medicaid Services. Medicare Part D Formulary Reference File 2026. CMS. 2026.
5. Surescripts. Prior Authorization Best Practices: Impact of Complete Documentation on First-Pass Approval Rates. Surescripts. 2024.
6. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021.
7. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022.
8. Eli Lilly and Company. Mounjaro Prescribing Information. Lilly USA. 2024.
9. Eli Lilly and Company. Zepbound Prescribing Information. Lilly USA. 2024.
10. Kaiser Family Foundation. Marketplace Plan Formulary Analysis: Coverage of Anti-Obesity Medications. KFF. 2026.
11. Congressional Budget Office. The Treat and Reduce Obesity Act: Budget Impact Analysis. CBO. 2025.
12. GoodRx Research. Retail Cash Prices for GLP-1 Medications: Q1 2026 Survey. GoodRx. 2026.
13. America's Health Insurance Plans. Copay Accumulator Programs: Prevalence and Impact on Patient Out-of-Pocket Costs. AHIP. 2025.
14. National Community Pharmacists Association. Pharmacy Benefit Manager Practices and Negotiated Drug Pricing. NCPA. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Ozempic, and Wegovy are registered trademarks of their respective manufacturers (Eli Lilly and Company, Novo Nordisk A/S). Medicare, Medicaid, and TRICARE are U.S. government programs. GoodRx, CoverMyMeds, and Surescripts are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these entities.